An observational study in Hereditary Cancer Syndromes, sponsored by National Cancer Centre, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by National Cancer Centre, Singapore · Observational
This study aims to assess the feasibility of implementing an AI-based hereditary cancer preliminary screening system that has already been developed. This validation cohort will consist of healthy individuals and cancer patients, including those already suspected to be at risk of hereditary conditions.
The preliminary screening of genetic cancer risk is not currently practical in cancer patients and healthy populations. It is time-consuming, inconsistent in quality, and inefficient when conducted manually. Given these limitations, artificial intelligence (AI) has gained attention as a potential tool for genetic risk assessment. Among AI technologies, Chatbots have been explored for their ability to facilitate patient communication and provide preliminary risk assessment, particularly in the context of hereditary cancers.
The investigators recently developed a new AI-based hereditary cancer preliminary screening system to identify high-risk people with genetic backgrounds. This system can assess the risk for hereditary breast and ovarian cancer (HBOC), lynch syndrome, and Li-Fraumeni syndrome, the major hereditary diseases. By conducting a feasibility study in Singapore, the investigators aim to assess the applicability of this system. The study will be conducted at the National Cancer Centre Singapore (NCCS), targeting both patients and members of the general Singaporean population. This system is expected to improve efficiency, ensure consistent quality, and expand access to genetic healthcare services across different populations and regions by automating preliminary screening. The system will be utilized to evaluate its operation completion rate and medical accuracy. After using the system, a survey will be conducted among the study participants to assess the system's usability.
46 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 25 are open to participants now.
This study's planned enrollment of 200 is below the median of 667 across 24 observational studies indexed under Neoplastic Syndromes, Hereditary.
Browse Neoplastic Syndromes, Hereditary studies →National Cancer Centre, Singapore is the lead sponsor of 117 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Both patients and the healthy population in Singapore.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group/Cohort Description: the system will be utilized to evaluate its operation completion rate and medical accuracy.
Other: Hereditary cancer preliminary screening chatbot
Patients will answer questions through the chatbot interface, which evaluates whether they meet HBOC, lynch syndrome, and Li-Fraumeni syndrome testing criteria based on their personal and family medical history. After using the system, a survey will be conducted among the study participants to assess the system's usability.
Completion rate
Completion rate of the hereditary cancer preliminary screening system using the Chatbot
Time frame: Immediately after completion of chatbot assessment.
Chatbot assessment completion time
Time required to operate the hereditary cancer preliminary screening system using the Chatbot.
Time frame: Immediately after completion of chatbot assessment.
Consistency rate
Consistency rate between the medical and family history related to hereditary cancers collected by the Chatbot and those provided by participants.
Time frame: Immediately after completion of chatbot assessment.
System Usability Scale score and participant feedback
Quantitative and qualitative data from multiple-choice and open-ended questionnaire surveys using the System Usability Scale.
Time frame: Immediately after completion of chatbot assessment and questionnaire, up to 1 day.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Syndromes, Hereditary →
National Cancer Centre, Singapore →